Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.

Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB 3rd.

Oncologist. 2019 Aug;24(8):1039-e642. doi: 10.1634/theoncologist.2019-0330. Epub 2019 May 28.

2.

A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.

Guo NL, Dowlati A, Raese RA, Dong C, Chen G, Beer DG, Shaffer J, Singh S, Bokhary U, Liu L, Howington J, Hensing T, Qian Y.

EBioMedicine. 2018 Jun;32:102-110. doi: 10.1016/j.ebiom.2018.05.025. Epub 2018 Jun 1.

3.

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer.

Shah S, Wood K, Labadie B, Won B, Brisson R, Karrison T, Hensing T, Kozloff M, Bao R, Patel JD, Luke JJ.

Oncotarget. 2017 Dec 15;9(4):4375-4384. doi: 10.18632/oncotarget.23315. eCollection 2018 Jan 12.

4.

KRAS in Non-Small-Cell Lung Cancer-Reply.

Wood K, Hensing T, Salgia R.

JAMA Oncol. 2016 Oct 1;2(10):1373-1374. doi: 10.1001/jamaoncol.2016.2347. No abstract available.

PMID:
27442777
5.

Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.

Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE.

Expert Rev Anticancer Ther. 2016 Aug;16(8):847-58. doi: 10.1080/14737140.2016.1202116. Epub 2016 Jul 11. Review.

PMID:
27400139
6.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.

Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.

7.

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.

Wood K, Hensing T, Malik R, Salgia R.

JAMA Oncol. 2016 Jun 1;2(6):805-12. doi: 10.1001/jamaoncol.2016.0405. Review.

PMID:
27100819
8.

The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative.

Won B, Carey GB, Tan YH, Bokhary U, Itkonen M, Szeto K, Wallace J, Campbell N, Hensing T, Salgia R.

Cureus. 2016 Mar 16;8(3):e533. doi: 10.7759/cureus.533.

9.

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.

Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R.

Oncotarget. 2016 Apr 5;7(14):18876-86. doi: 10.18632/oncotarget.7739.

10.

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G.

J Clin Oncol. 2016 Mar 20;34(9):987-1011. doi: 10.1200/JCO.2015.65.8427. Epub 2016 Feb 4. No abstract available.

11.

Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit.

Rosenberg CA, Flanagan C, Brockstein B, Obel JC, Dragon LH, Merkel DE, Wade EL, Law TM, Khandekar JD, Hensing TA.

J Cancer Surviv. 2016 Feb;10(1):206-19. doi: 10.1007/s11764-015-0467-6. Epub 2015 Jul 16.

PMID:
26178325
12.

Lung cancer-a fractal viewpoint.

Lennon FE, Cianci GC, Cipriani NA, Hensing TA, Zhang HJ, Chen CT, Murgu SD, Vokes EE, Vannier MW, Salgia R.

Nat Rev Clin Oncol. 2015 Nov;12(11):664-75. doi: 10.1038/nrclinonc.2015.108. Epub 2015 Jul 14. Review.

13.

Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.

Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR.

Oncoscience. 2014 Aug 7;1(8):522-528. eCollection 2014.

14.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R.

J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405.

15.

Outpatient advance care planning for patients with metastatic cancer: a pilot quality improvement initiative.

Obel J, Brockstein B, Marschke M, Robicsek A, Konchak C, Sefa M, Ziomek N, Benfield T, Peterson C, Gustafson C, Eriksson J, Harper A, Tabachow C, Raymond M, Hensing T.

J Palliat Med. 2014 Nov;17(11):1231-7. doi: 10.1089/jpm.2014.0085. Epub 2014 Oct 24.

PMID:
25343403
16.

Buccal spectral markers for lung cancer risk stratification.

Radosevich AJ, Mutyal NN, Rogers JD, Gould B, Hensing TA, Ray D, Backman V, Roy HK.

PLoS One. 2014 Oct 9;9(10):e110157. doi: 10.1371/journal.pone.0110157. eCollection 2014.

17.

Buccal microRNA dysregulation in lung field carcinogenesis: gender-specific implications.

Wali RK, Hensing TA, Ray DW, Dela Cruz M, Tiwari AK, Radosevich A, Jepeal L, Fernando HC, Litle VR, Charlot M, Momi N, Backman V, Roy HK.

Int J Oncol. 2014 Sep;45(3):1209-15. doi: 10.3892/ijo.2014.2495. Epub 2014 Jun 11.

18.

Molecular pathways and therapeutic targets in lung cancer.

Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R.

Oncotarget. 2014 Mar 30;5(6):1392-433. Review.

19.

A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.

Hensing T, Chawla A, Batra R, Salgia R.

Adv Exp Med Biol. 2014;799:85-117. doi: 10.1007/978-1-4614-8778-4_5. Review.

PMID:
24292963
20.

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA.

J Clin Oncol. 2013 Sep 20;31(27):3320-6. doi: 10.1200/JCO.2013.51.1816. Epub 2013 Aug 26.

21.

Molecular biomarkers for future screening of lung cancer.

Hensing TA, Salgia R.

J Surg Oncol. 2013 Oct;108(5):327-33. doi: 10.1002/jso.23382. Epub 2013 Jul 25. Review.

PMID:
23893423
22.

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE.

Chest. 2013 May;143(5 Suppl):e341S-e368S. doi: 10.1378/chest.12-2361.

23.

Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma.

Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, Armato SG 3rd, Kindler HL, Salgia R.

BMJ Open. 2012 Oct 26;2(5). pii: e001620. doi: 10.1136/bmjopen-2012-001620. Print 2012.

24.

Effect of an electronic health record on the culture of an outpatient medical oncology practice in a four-hospital integrated health care system: 5-year experience.

Brockstein B, Hensing T, Carro GW, Obel J, Khandekar J, Kaminer L, Van De Wege C, de Wilton Marsh R.

J Oncol Pract. 2011 Jul;7(4):e20-4. doi: 10.1200/JOP.2011.000260.

25.

A brief symptom index for advanced lung cancer.

Yount S, Beaumont J, Rosenbloom S, Cella D, Patel J, Hensing T, Jacobsen PB, Syrjala K, Abernethy AP.

Clin Lung Cancer. 2012 Jan;13(1):14-23. doi: 10.1016/j.cllc.2011.03.033. Epub 2011 May 23.

26.

A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.

Stinchcombe TE, Peterman AH, Lee CB, Moore DT, Beaumont JL, Bradford DS, Bakri K, Taylor M, Crane JM, Schwartz G, Hensing TA, McElroy E Jr, Niell HB, Harper HD, Pal S, Socinski MA.

J Thorac Oncol. 2011 Sep;6(9):1569-77. doi: 10.1097/JTO.0b013e3182210430.

27.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database.

Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia R.

J Clin Bioinforma. 2011 Feb 28;1(8):1-11. doi: 10.1186/2043-9113-1-8.

28.

Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.

Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA.

J Thorac Oncol. 2011 Aug;6(8):1418-25. doi: 10.1097/JTO.0b013e318220c93e.

29.

Personalized treatment of lung cancer.

Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE.

Semin Oncol. 2011 Apr;38(2):274-83. doi: 10.1053/j.seminoncol.2011.01.012. Review.

PMID:
21421117
30.

Mind-mapping for lung cancer: towards a personalized therapeutics approach.

Mollberg N, Surati M, Demchuk C, Fathi R, Salama AK, Husain AN, Hensing T, Salgia R.

Adv Ther. 2011 Mar;28(3):173-94. doi: 10.1007/s12325-010-0103-9. Epub 2011 Feb 9. Review.

31.

Generation of comprehensive thoracic oncology database--tool for translational research.

Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Kanteti R, Ferguson B, Gangadhar T, Hensing T, Hasina R, Husain A, Ferguson M, Karrison T, Salgia R.

J Vis Exp. 2011 Jan 22;(47). pii: 2414. doi: 10.3791/2414.

32.

Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification.

Roy HK, Hensing T, Backman V.

Future Oncol. 2011 Jan;7(1):1-3. doi: 10.2217/fon.10.176. No abstract available.

33.

Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening.

Roy HK, Subramanian H, Damania D, Hensing TA, Rom WN, Pass HI, Ray D, Rogers JD, Bogojevic A, Shah M, Kuzniar T, Pradhan P, Backman V.

Cancer Res. 2010 Oct 15;70(20):7748-54. doi: 10.1158/0008-5472.CAN-10-1686. Epub 2010 Oct 5.

34.

Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.

Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME.

J Natl Cancer Inst. 2010 Jan 6;102(1):47-53. doi: 10.1093/jnci/djp439. Epub 2009 Dec 9.

PMID:
20007525
35.

A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer.

Stinchcombe TE, Bradford DS, Hensing TA, LaRocca RV, Saleh M, Evans T, Bakri K, Socinski MA.

Cancer Invest. 2010 Feb;28(2):208-15. doi: 10.3109/07357900903286958.

PMID:
19916742
36.

Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy.

Subramanian H, Roy HK, Pradhan P, Goldberg MJ, Muldoon J, Brand RE, Sturgis C, Hensing T, Ray D, Bogojevic A, Mohammed J, Chang JS, Backman V.

Cancer Res. 2009 Jul 1;69(13):5357-63. doi: 10.1158/0008-5472.CAN-08-3895. Epub 2009 Jun 23.

37.

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD.

J Clin Oncol. 2009 Jul 10;27(20):3284-9. doi: 10.1200/JCO.2008.20.8181. Epub 2009 May 11.

PMID:
19433684
38.

The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.

Stinchcombe TE, Harper HD, Hensing TA, Moore DT, Crane JM, Atkins JN, Willard EM, Detterbeck FC, Socinski MA.

J Thorac Oncol. 2008 Feb;3(2):145-51. doi: 10.1097/JTO.0b013e318160c5f1.

39.

Prevalence of poor performance status in lung cancer patients: implications for research.

Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D.

J Thorac Oncol. 2008 Feb;3(2):125-9. doi: 10.1097/JTO.0b013e3181622c17.

40.

Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer.

Cella D, Eton D, Hensing TA, Masters GA, Parasuraman B.

Clin Lung Cancer. 2008 Jan;9(1):51-8. doi: 10.3816/CLC.2008.n.009.

PMID:
18282359
41.

Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy.

Cella D, Wagner L, Cashy J, Hensing TA, Yount S, Lilenbaum RC.

J Natl Cancer Inst Monogr. 2007;(37):53-60. Review.

PMID:
17951232
42.

An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration.

Davis K, Yount S, Del Ciello K, Whalen M, Khan S, Bass M, Du H, Eton D, Masters G, Hensing T, Cella D.

J Support Oncol. 2007 Sep;5(8):381-7.

PMID:
17944147
43.

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).

Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D; American College of Chest Physicians.

Chest. 2007 Sep;132(3 Suppl):277S-289S.

PMID:
17873174
44.

Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.

Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA.

J Thorac Oncol. 2007 Sep;2(9):845-53. Review.

45.

Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.

Hoang T, Kim K, Merchant J, Traynor AM, McGovern J, Oettel KR, Sanchez FA, Ahuja HG, Hensing TA, Larson M, Schiller JH.

J Thorac Oncol. 2006 Mar;1(3):218-25.

46.

Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.

Argiris A, Hensing T, Yeldandi A, Patel S, Raji A, Sturgis C, Masters G, Gooding W, Pins M, Kolesar J.

J Thorac Oncol. 2006 Jan;1(1):52-60.

47.

Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer.

Hensing TA, Hanna NH, Gillenwater HH, Gabriella Camboni M, Allievi C, Socinski MA.

Anticancer Drugs. 2006 Jul;17(6):697-704.

PMID:
16917215
48.

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.

Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J.

Lung Cancer. 2006 Sep;53(3):331-7. Epub 2006 Jun 23.

PMID:
16797779
49.

A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.

Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman AH, Niell HB.

Ann Oncol. 2006 Jan;17(1):104-9. Epub 2005 Oct 25.

PMID:
16249215
50.

Duration of therapy in advanced, metastatic non-small-cell lung cancer.

Socinski MA, Baggstrom MQ, Hensing TA.

Clin Adv Hematol Oncol. 2003 Jan;1(1):33-8.

PMID:
16227958

Supplemental Content

Loading ...
Support Center